Octreotide is under clinical development by Rani Therapeutics and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Octreotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Octreotide (RT-101) is under development for the treatment of acromegaly and neuroendocrine tumors. It is administered through oral route as capsule. It acts by targeting somatostatin receptor subtype 2 and subtype 5 (SSTR2 and SSTR5) and is being developed based on RaniPill technology platform.
Rani Therapeutics overview
Rani Therapeutics, a subsidiary of Rani Therapeutics Holdings Inc, is a clinical-stage biotherapeutics company. It has developed a technology for the oral delivery of biologics. The company’s pipeline products include RT-101, RT-102, RT-105, RT-110 and RT-111. Its product’s therapeutic areas include neuroendocrine tumors (NETs), acromegaly, osteoporosis, psoriatic arthritis, hypoparathyroidism and psoriasis. The company conducts research to develop its approach and technology through collaborations with life sciences laboratories. Its technology has the potential to transform the RaniPill capsule injecting the drug into the intestinal wall. Rani Therapeutics is headquartered in San Jose, California, the US.
For a complete picture of Octreotide’s drug-specific PTSR and LoA scores, buy the report here.